Trials / Active Not Recruiting
Active Not RecruitingNCT03158064
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
A Single-arm, Phase II Study of Durvalumab (MEDI4736) and Tremelimumab for Relapsed/Refractory Germ Cell Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety and effectiveness of durvalumab with tremelimumab in patients with relapsed or refractory germ cell tumors.
Conditions
- Germ Cell Tumor
- Nonseminomatous Germ Cell Tumor
- Seminoma
- Germinomatous Germ Cell Tumor
- Dysgerminoma
- Pineal Germ Cell Tumor
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Durvalumab | 1500 mg by IV |
| DRUG | Tremelimumab | 75 mg by IV \*300mg |
Timeline
- Start date
- 2017-05-15
- Primary completion
- 2026-11-01
- Completion
- 2026-11-01
- First posted
- 2017-05-17
- Last updated
- 2026-01-28
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03158064. Inclusion in this directory is not an endorsement.